公开(公告)号：WO2005044859A3

公开(公告)日：2005-08-04

申请号：PCT/IB2004003896

申请日：2004-11-05

Applicant: GLYCART BIOTECHNOLOGY AG ,  UMANA PABLO ,  BRUENKER PETER ,  FERRARA CLAUDIA ,  SUTER TOBIAS ,  PUENTENER URSULA ,  MOESSNER EKKEHARD

Inventor： UMANA PABLO ,  BRUENKER PETER ,  FERRARA CLAUDIA ,  SUTER TOBIAS ,  PUENTENER URSULA ,  MOESSNER EKKEHARD

IPC: A61K39/395 ,  C07H21/04 ,  C07K16/28 ,  C07K16/40 ,  C12N9/10 ,  C12P21/04 ,  C12Q1/68

CPC classification number: C07K16/2887 ,  A61K2039/505 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/53 ,  C07K2317/56 ,  C07K2317/567 ,  C07K2317/72 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/92 ,  C07K2319/01 ,  C12N9/1051 ,  C12N15/11 ,  C12N15/63 ,  C12Y204/01144 ,  Y10S530/808 ,  Y10S530/866 ,  Y10S530/867

Abstract: The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human CD20. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.

Abstract translation: 本发明涉及抗原结合分子（ABM）。 在具体实施方案中，本发明涉及重组单克隆抗体，包括对人CD20特异性的嵌合，灵长类或人源化抗体。 此外，本发明涉及编码这种ABM的核酸分子以及包含该核酸分子的载体和宿主细胞。 本发明还涉及生产本发明的ABM的方法以及使用这些ABM在治疗疾病中的方法。 此外，本发明涉及具有改善的治疗性质的具有改性糖基化的ABM，包括具有增加的Fc受体结合和增加的效应子功能的抗体。

公开(公告)号：WO2012107417A1

公开(公告)日：2012-08-16

申请号：PCT/EP2012/051991

申请日：2012-02-07

Applicant: ROCHE GLYCART AG ,  AST, Oliver ,  BRUENKER, Peter ,  FREIMOSER-GRUNDSCHOBER, Anne ,  HERTER, Sylvia ,  HOFER, Thomas U. ,  HOSSE, Ralf ,  KLEIN, Christian ,  MOESSNER, Ekkehard ,  NICOLINI, Valeria G. ,  UMANA, Pablo

Inventor： AST, Oliver ,  BRUENKER, Peter ,  FREIMOSER-GRUNDSCHOBER, Anne ,  HERTER, Sylvia ,  HOFER, Thomas U. ,  HOSSE, Ralf ,  KLEIN, Christian ,  MOESSNER, Ekkehard ,  NICOLINI, Valeria G. ,  UMANA, Pablo

IPC: C07K14/55 ,  C12N15/26 ,  A61K39/395 ,  A61K47/48

CPC classification number: C07K16/40 ,  A61K38/2013 ,  A61K47/6813 ,  A61K47/6849 ,  A61K47/6871 ,  A61K47/6891 ,  A61K2039/505 ,  C07K14/55 ,  C07K16/30 ,  C07K2319/00

Abstract: The present invention generally relates to mutant interleukin-2 polypeptides that exhibit reduced affinity to the α-subunit of the IL-2 receptor, for use as immunotherapeutic agents. In addition, the invention relates to immunoconjugates comprising said mutant IL-2 polypeptides, polynucleotide molecules encoding the mutant IL-2 polypeptides or immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant IL-2 polypeptides or immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.

Abstract translation: 本发明通常涉及对IL-2受体的α-亚单位表现出降低的亲和力的突变白细胞介素-2多肽，用作免疫治疗剂。 此外，本发明涉及包含所述突变型IL-2多肽，编码突变型IL-2多肽或免疫缀合物的多核苷酸分子以及包含该多核苷酸分子的载体和宿主细胞的免疫缀合物。 本发明还涉及用于产生突变型IL-2多肽或免疫缀合物的方法，包含其的药物组合物及其用途。

公开(公告)号：WO2004065540A3

公开(公告)日：2005-03-24

申请号：PCT/IB2004000844

申请日：2004-01-22

Applicant: GLYCART BIOTECHNOLOGY AG ,  UMANA PABLO ,  BRUENKER PETER ,  FERRARA CLAUDIA ,  SUTER TOBIAS

Inventor： UMANA PABLO ,  BRUENKER PETER ,  FERRARA CLAUDIA ,  SUTER TOBIAS

IPC: A61K38/00 ,  C07K16/28 ,  C07K16/30 ,  C07K16/32 ,  C12N9/10 ,  C12N9/24 ,  C12N15/62 ,  C12P21/00 ,  C07K16/00 ,  C12N15/54

CPC classification number: C07K16/2887 ,  A61K38/00 ,  A61K2039/505 ,  C07K16/28 ,  C07K16/2863 ,  C07K16/2896 ,  C07K16/30 ,  C07K16/32 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/732 ,  C07K2319/05 ,  C12N9/1051 ,  C12N9/2488 ,  C12N15/62 ,  C12P21/005 ,  C12Y204/01038 ,  C12Y204/01144 ,  C12Y302/01024 ,  C12Y302/01096 ,  C12Y302/01114

Abstract: The present invention relates to the field of glycosylation engineering of proteins. More particularly, the present invention relates to nucleic acid molecules, including fusion constructs, having catalytic activity and the use of same in glycosylation engineering of host cells to generate polypeptides with improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.

Abstract translation: 本发明涉及蛋白质的糖基化工程领域。 更具体地说，本发明涉及具有催化活性的核酸分子，包括具有催化活性的核糖分子，以及其在宿主细胞的糖基化工程中的用途，以产生具有改善的治疗性质的多肽，包括具有增加的Fc受体结合和增加的效应子功能的抗体。

公开(公告)号：WO2013026839A1

公开(公告)日：2013-02-28

申请号：PCT/EP2012/066226

申请日：2012-08-21

Applicant: ROCHE GLYCART AG ,  BRUENKER, Peter ,  FAUTI, Tanja ,  JAEGER, Christiane ,  KLEIN, Christian ,  UMANA, Pablo

Inventor： BRUENKER, Peter ,  FAUTI, Tanja ,  JAEGER, Christiane ,  KLEIN, Christian ,  UMANA, Pablo

IPC: A61K39/395 ,  A61P35/00 ,  C07K16/30

CPC classification number: C07K16/468 ,  C07K16/2809 ,  C07K16/30 ,  C07K16/3053 ,  C07K2317/31 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/66

Abstract: The present invention relates to bispecific antibodies that specifically bind a T-cell activating antigen and a Tumor Antigen (TA), comprising a first Fab fragment and a second Fab fragment, wherein either the variable regions or the constant regions of the second Fab heavy and light chain are exchanged; and wherein the bispecific antibody does not comprise a Fc domain; methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Abstract translation: 本发明涉及特异性结合T细胞活化抗原和肿瘤抗原（TA）的双特异性抗体，其包含第一Fab片段和第二Fab片段，其中第二Fab重链的可变区或恒定区 轻链交换; 并且其中所述双特异性抗体不包含Fc结构域; 其制备方法，含有所述抗体的药物组合物及其用途。

公开(公告)号：WO2013026833A1

公开(公告)日：2013-02-28

申请号：PCT/EP2012/066215

申请日：2012-08-21

Applicant: ROCHE GLYCART AG ,  AST, Oliver ,  BRUENKER, Peter ,  FAUTI, Tanja ,  FREIMOSER-GRUNDSCHOBER, Anne ,  JAEGER, Christiane ,  KLEIN, Christian ,  MOESSNER, Ekkehard ,  UMANA, Pablo

Inventor： AST, Oliver ,  BRUENKER, Peter ,  FAUTI, Tanja ,  FREIMOSER-GRUNDSCHOBER, Anne ,  JAEGER, Christiane ,  KLEIN, Christian ,  MOESSNER, Ekkehard ,  UMANA, Pablo

IPC: C07K16/30 ,  A61K39/395 ,  A61P35/00

CPC classification number: C07K16/468 ,  C07K16/2809 ,  C07K16/2863 ,  C07K16/3007 ,  C07K16/3053 ,  C07K16/40 ,  C07K2317/31 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/626 ,  C07K2317/64 ,  C07K2317/66 ,  C07K2317/73 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/00

Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.

Abstract translation: 本发明总体上涉及用于T细胞活化和重定向至特定靶细胞的新型双特异性抗原结合分子。 此外，本发明涉及编码此类双特异性抗原结合分子的多核苷酸，以及包含此类多核苷酸的载体和宿主细胞。 本发明进一步涉及生产本发明双特异性抗原结合分子的方法，以及使用这些双特异性抗原结合分子治疗疾病的方法。

公开(公告)号：WO2013026831A1

公开(公告)日：2013-02-28

申请号：PCT/EP2012/066213

申请日：2012-08-21

Applicant: ROCHE GLYCART AG ,  AUER, Johannes ,  BRUENKER, Peter ,  FAUTI, Tanja ,  JAEGER, Christiane ,  KLEIN, Christian ,  SCHAEFER, Wolfgang ,  SUSTMANN, Claudio ,  UMANA, Pablo

Inventor： AUER, Johannes ,  BRUENKER, Peter ,  FAUTI, Tanja ,  JAEGER, Christiane ,  KLEIN, Christian ,  SCHAEFER, Wolfgang ,  SUSTMANN, Claudio ,  UMANA, Pablo

IPC: C07K16/30 ,  A61K39/395 ,  A61P35/00

CPC classification number: C07K16/2809 ,  C07K16/3053 ,  C07K16/468 ,  C07K2317/31 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/626 ,  C07K2317/64 ,  C07K2317/66 ,  C07K2317/73 ,  C07K2317/92 ,  C07K2319/00

Abstract: The present invention generally relates to novel bispecific antigen binding molecules. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.

Abstract translation: 本发明一般涉及新的双特异性抗原结合分子。 此外，本发明涉及编码这种双特异性抗原结合分子的多核苷酸，以及包含这种多核苷酸的载体和宿主细胞。 本发明还涉及用于产生本发明的双特异性抗原结合分子的方法以及在治疗疾病中使用这些双特异性抗原结合分子的方法。

公开(公告)号：WO2004065540A2

公开(公告)日：2004-08-05

申请号：PCT/IB2004/000844

申请日：2004-01-22

Applicant: GLYCART BIOTECHNOLOGY AG ,  UMANA, Pablo ,  BRUENKER, Peter ,  FERRARA, Claudia ,  SUTER, Tobias

Inventor： UMANA, Pablo ,  BRUENKER, Peter ,  FERRARA, Claudia ,  SUTER, Tobias

IPC: C12N

CPC classification number: C07K16/2887 ,  A61K38/00 ,  A61K2039/505 ,  C07K16/28 ,  C07K16/2863 ,  C07K16/2896 ,  C07K16/30 ,  C07K16/32 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/732 ,  C07K2319/05 ,  C12N9/1051 ,  C12N9/2488 ,  C12N15/62 ,  C12P21/005 ,  C12Y204/01038 ,  C12Y204/01144 ,  C12Y302/01024 ,  C12Y302/01096 ,  C12Y302/01114

Abstract: The present invention relates to the field of glycosylation engineering of proteins. More particularly, the present invention relates to nucleic acid molecules, including fusion constructs, having catalytic activity and the use of same in glycosylation engineering of host cells to generate polypeptides with improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.

Abstract translation: 本发明涉及蛋白质的糖基化工程领域。 更具体地说，本发明涉及具有催化活性的核酸分子，包括具有催化活性的核糖分子，以及其在宿主细胞的糖基化工程中的用途，以产生具有改善的治疗性质的多肽，包括具有增加的Fc受体结合和增加的效应子功能的抗体。

公开(公告)号：WO2013026835A1

公开(公告)日：2013-02-28

申请号：PCT/EP2012/066219

申请日：2012-08-21

Applicant: ROCHE GLYCART AG ,  BRUENKER, Peter ,  JAEGER, Christiane ,  KLEIN, Christian ,  SCHAEFER, Wolfgang ,  UMANA, Pablo

Inventor： BRUENKER, Peter ,  JAEGER, Christiane ,  KLEIN, Christian ,  SCHAEFER, Wolfgang ,  UMANA, Pablo

IPC: C07K16/30 ,  A61P35/00

CPC classification number: C07K16/468 ,  C07K2317/55 ,  C07K2317/66

Abstract: The present invention relates to bispecific antibodies comprising at least two fab fragments, wherein the first Fab fragment comprises at least one antigen binding site specific for a first antigen; and the second Fab fragment comprises at least one antigen binding site specific for a second antigen,wherein either the variable regions or the constant regions of the second Fab heavy and light chain are exchanged; and wherein the bispecific antibody is devoid of a Fc domain; methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Abstract translation: 本发明涉及包含至少两个fab片段的双特异性抗体，其中第一Fab片段包含至少一个对第一抗原特异的抗原结合位点; 并且所述第二Fab片段包含至少一个针对第二抗原特异性的抗原结合位点，其中所述第二Fab重链和轻链的可变区或恒定区被交换; 并且其中所述双特异性抗体缺乏Fc结构域; 其制备方法，含有所述抗体的药物组合物及其用途。

公开(公告)号：WO2012146628A1

公开(公告)日：2012-11-01

申请号：PCT/EP2012/057587

申请日：2012-04-26

Applicant: ROCHE GLYCART AG ,  AST, Oliver ,  BRUENKER, Peter ,  HOFER, Thomas U. ,  HOSSE, Ralf ,  KLEIN, Christian ,  MOESSNER, Ekkehard ,  UMANA, Pablo

Inventor： AST, Oliver ,  BRUENKER, Peter ,  HOFER, Thomas U. ,  HOSSE, Ralf ,  KLEIN, Christian ,  MOESSNER, Ekkehard ,  UMANA, Pablo

IPC: C07K14/55 ,  C12N15/26 ,  A61K39/395 ,  A61K47/48 ,  C07K16/46 ,  C07K19/00 ,  C07K14/54

CPC classification number: C07K16/40 ,  A61K38/2013 ,  A61K39/395 ,  A61K47/6813 ,  A61K47/6843 ,  A61K47/6849 ,  A61K47/6851 ,  A61K47/6853 ,  A61K2039/505 ,  C07K14/52 ,  C07K14/5434 ,  C07K14/55 ,  C07K16/18 ,  C07K16/283 ,  C07K16/2866 ,  C07K16/30 ,  C07K16/3007 ,  C07K16/46 ,  C07K2317/21 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/524 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/71 ,  C07K2317/732 ,  C07K2317/92 ,  C07K2319/00 ,  C07K2319/30 ,  C07K2319/33 ,  C07K2319/74

Abstract: The present invention generally relates to antigen-specific immunoconjugates for selectively delivering effector moieties that influence cellular activity. More specifically, the invention provides novel immunoconjugates comprising a first antigen binding moiety, an Fc domain and a single effector moiety. In addition, the present invention relates to polynucleotides encoding such immunoconjugates, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the immunoconjugates of the invention, and to methods of using these immunoconjugates in the treatment of disease.

Abstract translation: 本发明一般涉及用于选择性递送影响细胞活性的效应部分的抗原特异性免疫偶联物。 更具体地，本发明提供了包含第一抗原结合部分，Fc结构域和单个效应子部分的新型免疫偶联物。 此外，本发明涉及编码这种免疫缀合物的多核苷酸，以及包含这种多核苷酸的载体和宿主细胞。 本发明还涉及本发明的免疫缀合物的制备方法，以及使用这些免疫缀合物治疗疾病的方法。

公开(公告)号：WO2011039126A1

公开(公告)日：2011-04-07

申请号：PCT/EP2010/064209

申请日：2010-09-27

Applicant: ROCHE GLYCART AG ,  BRUENKER, Peter ,  FERRARA KOLLER, Claudia ,  GRAU, Sandra ,  HERTER, Sylvia ,  LAMPERT, Christoph ,  MOESSNER, Ekkehard ,  UMANA, Pablo ,  WALDHAUER, Inja

Inventor： BRUENKER, Peter ,  FERRARA KOLLER, Claudia ,  GRAU, Sandra ,  HERTER, Sylvia ,  LAMPERT, Christoph ,  MOESSNER, Ekkehard ,  UMANA, Pablo ,  WALDHAUER, Inja

IPC: C07K16/28 ,  C07K16/30 ,  C07K16/18 ,  C07K16/40

CPC classification number: C07K16/2878 ,  C07K16/18 ,  C07K16/30 ,  C07K16/3007 ,  C07K16/40 ,  C07K2317/31 ,  C07K2317/73

Abstract: The present invention relates to bispecific antibodies comprising a first antigen binding site specific for a death receptor and a second antigen binding site specific for a second antigen, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Abstract translation: 本发明涉及包含对死亡受体特异性的第一抗原结合位点和第二抗原特异性的第二抗原结合位点的双特异性抗体，其制备方法，含有所述抗体的药物组合物及其用途。